Vertigo After Menopause: What the BPPV Research Actually Shows

How common is vertigo after menopause?

Benign paroxysmal positional vertigo, almost always shortened to BPPV, is the most common vestibular disorder seen in emergency departments and ear, nose and throat clinics. Lifetime prevalence sits near 10 percent, which works out to more than 420 million adults worldwide.

It is also the condition people most often mistake for something far more frightening.

A few numbers worth holding onto before we get to the mechanism, all drawn from the published literature.

• BPPV is set off by a change in head position rather than by standing up too quickly, and the spinning usually lasts less than a minute
• Somewhere between 15 and 30 percent of patients have a recurrence within the first year after successful treatment
• Cumulative recurrence rates climb toward 50 percent over 10 years
• Epidemiological work cited by the Sichuan multicenter team puts BPPV incidence in postmenopausal women at 2 to 3 times the rate reported in men

Why it gets filed under getting older

Most women who have had BPPV describe it the same way. The room moved, it stopped, and they never mentioned it again because it seemed like a fluke or a bad night's sleep.

Three reasons it rarely gets named correctly, even by women who have had it repeatedly.

• The attacks are over in seconds, so by the time anyone asks about it, the room has long stopped moving
• Dizziness is one word covering lightheadedness, unsteadiness and true spinning, and only the last of those points at the inner ear
• Menopause appointments tend to cover hot flashes, sleep and bone density, and balance rarely makes the list at all

What is actually happening inside the inner ear?

Sitting on top of the balance organ in each inner ear is a layer of microscopic crystals called otoconia. They are made of calcium carbonate, the same mineral compound as chalk and eggshell, and their weight is what lets the brain sense which way is down.

In BPPV, some of those crystals break loose and drift into the semicircular canals, where they do not belong. Head movement then sloshes them through fluid that is supposed to stay still, and the brain receives a signal saying the world is spinning when it is not.

This matters for a reason most articles skip. Otoconia are not permanent structures. They are continuously worn down and rebuilt, mineralized by calcium ions drawn from the fluid around them, which means anything that disturbs calcium handling in the body can reach them.

The two problems share an organ and share a hormone, and they are otherwise not the same condition at all. Confusing them is easy, and it sends women looking for answers in the wrong literature.

The calcium paradox researchers describe

Here the picture gets genuinely counterintuitive, and the Sichuan team spells it out.

When estrogen falls and bone resorption speeds up, calcium is pulled out of the skeleton and into circulation, which can briefly push serum calcium up. Underneath that, chronic vitamin D deficiency is quietly wrecking the body's ability to regulate calcium at all. The surface reading looks fine while the control system fails.

Their paper describes low serum calcium destabilizing otoconia through three routes, including reduced mineralization efficiency of otoconin-90, the matrix protein the crystals are built on, and abnormal shedding of crystals that have not fully hardened.

Does estrogen loss really drive it, or is that just a theory?

This is where the 2025 study earns its place, because it put numbers on the question in real patients rather than arguing from mechanism.

Qing-Chun Pan, Bei Li and Kai Zou analyzed 490 postmenopausal women diagnosed with BPPV and successfully treated with canalith repositioning across 5 hospitals in Sichuan Province, China, between January 2019 and January 2024. Within 1 year, 151 of them, or 30.82 percent, had the vertigo come back. Four factors independently predicted it.

Three of those four are the mineral and hormone axis, pointing the same direction, in the same women. Osteoporosis was already present in about 33.5 percent of the group.

The team lays out how estrogen reaches the inner ear at all, and it runs through bone. Falling estrogen increases bone resorption and reduces bone density, which alters the composition of the otoconia themselves. Estrogen also promotes calcitonin secretion, so when estrogen drops, calcitonin drops with it, calcium metabolism is disrupted, and free calcium ions rise in the inner ear fluid where the crystals are supposed to be quietly dissolving and rebuilding.

What the animal work adds

Human association studies can only take this so far, so it helps that two research groups went and looked at the crystals directly.

• A Shanghai team led by Yang found estradiol was significantly lower in postmenopausal women with idiopathic BPPV than in controls, at P less than .001, then showed in ovariectomized rats that estradiol replacement reversed the drop in otoconin-90
• A Japanese group led by Nakata used micro-CT to measure the otoconial layer in ovariectomized mice and found it was significantly altered compared with sham-operated animals
• In that same study, both estradiol and raloxifene protected the otoconial layer, and the marker that tracked the damage was 4-hydroxynonenal, a measure of oxidative stress

That last detail is the one worth underlining. Nakata's group concluded the protection worked via oxidative stress reduction, which turns a hormone story into a mineral and oxidative-stress story.

Do minerals change anything, or is repositioning the only answer?

Repositioning is the answer to an attack, and nothing here changes that. The canalith repositioning procedure is a short sequence of guided head movements performed by an ENT or a vestibular therapist that settles the loose crystals back into the chamber they escaped from, and it resolves most cases quickly.

The open question has always been recurrence. One randomized trial addressed it head on.

Across 8 hospitals, 518 patients were assigned to supplementation and 532 to observation after successful repositioning. Those in the intervention group took vitamin D and calcium twice daily for a year when their serum vitamin D was below 20 nanograms per milliliter.

• Annual recurrence dropped to 0.83 episodes per person-year against 1.10 in the observation group
• The share of patients with any recurrence fell from 46.7 percent to 37.8 percent, at p equal to .005
• The number needed to treat came out at 3.70, which is a strong figure for a preventive nutrient intervention

What that trial does not say

It does not say minerals fix vertigo. It says correcting a documented deficiency lowered how often it returned, in people who had already been treated properly.

It also does not say anything whatsoever about shilajit. That trial gave vitamin D and calcium, and the credit for the result belongs there.

What does shilajit's own research show?

Start with the boundary, because it is absolute. No human trial, and no animal study, has ever given shilajit and measured a vertigo, BPPV or otoconia outcome. A PubMed search pairing shilajit with vertigo, with the vestibular system, or with otoconia returns zero results. Anyone telling you otherwise is inventing it.

What shilajit does have is a 48-week double-blind randomized trial in 60 postmenopausal women, led by Pingali, and it happens to have measured the two exact processes the vertigo research keeps naming.

The first is bone resorption. The Sichuan team's leading explanation for why otoconia degrade after menopause is accelerated bone resorption altering their composition. In Pingali's trial, CTX-1, the standard marker of bone resorption, fell 17.7 percent at the lower dose and 21.8 percent at the higher one by week 48, while it rose in the placebo group. Every single woman who took it reversed her osteoporosis.

The second is oxidative stress. Nakata's mice pointed at oxidative stress as the route by which estrogen deficiency damages the otoconial layer. Pingali measured MDA, a marker of oxidative damage, down 20.5 percent, and glutathione, the body's own antioxidant, up 37.0 percent.

Shilajit is not a hormone. It supports the body's own estrogen signaling, which is the mechanism behind both of those results.

Where the bridge holds and where it stops

It holds in one specific way. The pathway the vertigo researchers keep pointing at, mineral metabolism running downstream of estrogen signaling, is the same pathway shilajit's own trial measured directly in postmenopausal women.

It stops immediately after that.

• Nobody has given a woman shilajit and looked at her inner ear, so no result here is a vertigo result
• Shilajit is a mineral resin carrying fulvic acid and 80 or more trace minerals, and it is not a vitamin D supplement, which is what the recurrence trial actually used
• Sharing a mechanism with a condition is not the same as being tested against it, and this article will not pretend otherwise
• BPPV is treated with repositioning, and no supplement substitutes for getting the crystals put back

Optimum is a small, family owned company out of Florida. Its resin comes from the Altai mountains, cold pressed with no heat processing, third party tested for heavy metals on every batch, and there have been zero serious adverse events ever reported across any human shilajit study.

Optimum Shilajit

If the mineral and estrogen-signaling pathway in this article is the one you want supported, with the fulvic acid and trace minerals studied in postmenopausal women, here is Optimum Shilajit.

See Optimum Shilajit